Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literature

References

• Groll AH, Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect 2001;7\(Suppl. 2):8–24
   Google Scholar
• Rolston K. Overview of systemic fungal infections. Oncology 2001;15\(Suppl. 9):11–4
   Google Scholar
• Sabra R, Branch RA. Amphotericin B nephrotoxicity. Drug Safety 1990;5:94–108
   PubMed Web of Science ®Google Scholar
• Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12: 308–29
   Google Scholar
• Dix SP, Wingard JR. Amphotericin B lipid complex: review of safety, pharmacokinetics and efficacy. Drugs of Today 1996;32:411–6
   Web of Science ®Google Scholar
• Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B. J Liposome Res 1998;8:443–67
   Web of Science ®Google Scholar
• Rapp RP, Gubbins PO, Evans ME. Amphotericin B lipid complex. Ann Pharmacother 1997;31:1174–86
   PubMedGoogle Scholar
• Mehta J. Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations? Leukemia Res 1997;21:183–8
   PubMed Web of Science ®Google Scholar
• Dix SP, Andriole VT. Lipid formulations of amphotericin B. Curr Clin Top Infect Dis 2000;20:1–23
   PubMedGoogle Scholar
• Janoff AS, Perkins WR, Saletan SL, Swenson CE. Amphotericin B lipid complex (ABLC™): a molecular rationale for the attenuation of amphotericin B related toxicities. J Liposomes Res 1993;3(3):451–71
   Google Scholar
• Adedoyin A, Bernardo JF, Swenson CE, et al. Pharmacokinetic profile of Abelcet (amphotericin B lipid complex injection): combined experience from phase I and phase II studies. Antimicrob Agents Chemother 1997;41:2201–8
   PubMed Web of Science ®Google Scholar
• Bhamra R, Sa’ad A, Bolcsak LE, Janoff AS, Swenson CE. Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats. Antimicrob Agents Chemother 1997;41:886–92
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Jackson AJ, Lee JW, et al. Dose-dependent pharmacokinetics of amphotericin B lipid complex in rabbits. Antimicrob Agents Chemother 2000;44:2068–76
   PubMed Web of Science ®Google Scholar
• Trouet A. The amphotericin B lipid complex or Abelcet: its Belgian connection, its mode of action and specificity: a review. Acta Clinica Belgica 2002;57:53–7
   PubMed Web of Science ®Google Scholar
• Williams P, Waskin H, Bolcsak L, Swenson C. Amphotericin B concentrations in autopsy tissues of organ transplant patients administered amphotericin B lipid complex injection. Transplantation 1999;67:593
   Google Scholar
• Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998;27:603–18
   PubMed Web of Science ®Google Scholar
• Swenson CE, Perkins WR, Roberts P, et al. In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important? Antimicrobial Agents Chemother 1998;42:767–71
   PubMed Web of Science ®Google Scholar
• Johnson EM, Ojwang JO, Szekely A, Wallace TL, Warnock DW. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob Agents Chemother 1998;42:1412–6
   Google Scholar
• Legrand P, Chéron M, Leroy L, Bolard J. Release of amphotericin B from delivery systems and its action against fungal and mammalian cells. J Drug Targeting 1997;4:311–19
   PubMed Web of Science ®Google Scholar
• Oakley KL, Moore CB, Denning DW. Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole. Antimicrob Agents Chemother 1999;43:1264–6
   Google Scholar
• Adedoyin A, Swenson CE, Bolcsak LE, et al. A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections. Antimicrob Agents Chemother 2000;44:2900–2
   PubMed Web of Science ®Google Scholar
• Elan Pharma Ltd. Amphotericin B lipid complex (Abelcet®): summary of product characteristics. 1 October 2001. PL: 16804/0018
   Google Scholar
• Tambyah PA, Zilz MA, Maki DG. A comparison of amphotericin B lipid complex (ABLC) with conventional amphotericin B for the treatment of invasive aspergillosis. 8th International Congress on Infectious Diseases; Boston, Massachusetts; 15–18 May 1998 [Abstract 23.024]
   Google Scholar
• Linden PK, Coley K, Fontes P, Fung JJ, Kusne S. Invasive aspergillosis in liver transplant recipients: comparison of therapy with amphotericin B lipid complex and a historical cohort treated with conventional amphotericin B therapy. Clin Infect Dis 2003;37:17–25
   Google Scholar
• Clark AD, McKendrick S, Tansey PJ, Franklin IM, Chopra R. A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology. Br J Haematol 1998;103:198–204
   Google Scholar
• Fortun J, Munoz P, Montejo M, et al. Efficacy and safety of AmBisome and Abelcet in transplant patients: a multicenter study. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 1999;39:574
   Google Scholar
• Lacerda JMF, Gomez B, Martins C, et al. Comparative analysis of liposomal (AmBisome-AMB) and lipid complex (Abelcet-ABLC) amphotericin B preparations after intensive and myeloablative chemotherapy regimens. Presented at the 41st ASH; New Orleans, Louisiana; 3–7 December 1999 [Abstract 4438]
   Google Scholar
• Tarragó D, Fortún J, Prieto MD, et al. Efficacy and safety of Abelcet™ and ambisome™ in fungal infections after liver transplantation. Presented at the Focus on Fungal Infections 9; 17–19 March, 1999 [Abstract 037]
   Google Scholar
• Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A, and the L Amph/ABLC Collaborative Study Group. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000;31:1155–63
   Google Scholar
• Cannon JP, Garey KW, Danziger LH. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacother 2001;21:1107–14
   Google Scholar
• Fleming RV, Kantarjian HM, Husni R, et al. Comparison of amphotericin B lipid complex (ABLC) vs. AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leukemia Lymphoma 2001;40:511–20
   Google Scholar
• Kuti JL, Kotapati S, Williams P, Capitano B, Nightingale CH, Nicolau DP. Pharmacoeconomic analysis of amphotericin B lipid complex (ABLC) versus liposomal amphotericin B (L-AmB) in the treatment of fungal infections. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 2002;42 [Abstract 0–1000]
   Google Scholar
• Hovsepian M, Lee P, Goldstein B. Comparison of safety and cost-effectiveness of Abelcet® and Amphotec®. American Society of Hospital Pharmacists, Las Vegas; December 1999 [poster]
   Google Scholar
• Sundar S, Agrawal NK, Sinha PR, Horwith GS, Murray HW. Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med 1997;127:133–37
   Google Scholar
• Sundar S, Goyal AK, More DK, Singh MK, Murray HW. Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex. Ann Trop Med Parasitol 1998;92:755–64
   Google Scholar
• Sundar S, Goyal AK, Mandal AK, Makharia MK, Singh VP, Murray HW. Amphotericin B lipid complex in the management of antimony-unresponsive Indian visceral leishmaniasis. J Assoc Physicians India 1999;47:186–8
   PubMedGoogle Scholar
• Anaissie EJ, White MH, Uzun O, et al. Amphotericin B lipid complex vs. amphotericin B for treatment of invasive candidiasis: a prospective, randomized multicenter trial. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 1995;35 [Abstract 330]
   Google Scholar
• Hiemenz JW, Lister J, Anaissie EJ, et al. Emergency-use amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis: historical-control comparison with amphotericin B. Blood 1995;86\(Suppl. 1):849a
   Google Scholar
• Sharkey PK, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22:315–21
   PubMed Web of Science ®Google Scholar
• Singletary TJ, Fish DN, Zamora MR, Hodges TN. Safety and efficacy of amphotericin B lipid complex in thoracic transplantation. Presented at the American College of Chest Physicians; New Orleans, LA; 26–30 October 1997 [Abstract]
   Google Scholar
• Macaulay SS, Martin JE, Zarnke KB. Amphotericin B for the treatment of systemic fungal infections: meta-analysis of conventional versus lipid formulations. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 2002;42 (Abstract M–888)
   Google Scholar
• Barrett JP, Vardulaki KA, Conlon C,et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003;25:1295–320
   Google Scholar
• Sastre JL, Cotallo C, Colomer F, Waskin H. Invasive neonatal candidiasis in Spain. Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 2000;40 [Abstract 383]
   Google Scholar
• Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383–96
   PubMed Web of Science ®Google Scholar
• Ito JI, with the CLEAR™ Steering Committee. Results from the CLEAR™ (Collaborative Exchange of Antifungal Research) program: analysis of 929 patients. Presented at the Focus on Fungal Infections 8; Orlando, Florida; 4–6 March 1998
   Google Scholar
• Kubak BM with the CLEAR Steering Committee. Salvage therapy in invasive aspergillosis with the use of amphotericin B lipid complex. Presented at the Infectious Diseases Society of America 37th Meeting; Philadelphia, Pennsylvania; 18–21 November 1999
   Google Scholar
• Larkin JA, Montero JA. Efficacy and safety of amphotericin B lipid complex for zygomycosis. Infect Med 2003;20:201–6
   Web of Science ®Google Scholar
• Baddour LM with the Collaborative Exchange of Antifungal Research (CLEAR) Steering Committee. Early response to ABLC among patients with CNS cryptococcal infections. Blood 2000;96\(Suppl. 1):438A
   Google Scholar
• Wiley JM, Matera JA. Amphotericin B lipid complex (ABLC) is effective against fluconazole-resistant Candida species infections. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 2001;41 [Abstract 359]
   Google Scholar
• Baddour LM. Blastomycosis and histoplasmosis: early response to amphotericin B lipid complex. Infect Med 2002;19:119–21
   Web of Science ®Google Scholar
• Gelone SP. Abelcet treatment in patients who failed or were intolerant to prior Ambisome therapy. Blood 2000;96:389B
   Google Scholar
• Merhav H, Mieles L. Amphotericin B lipid complex in the treatment of invasive fungal infections in liver transplant patients. Transplant Proc 1997;29:2670–4
   PubMed Web of Science ®Google Scholar
• Linden P, Williams P, Chan KM. Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections. Clin Transplant 2000;14:329–39
   Google Scholar
• Martino R, Subirá M, Sureda A, Sierra J. Amphotericin B lipid complex at 3 mg/kg/day for treatment of invasive fungal infections in adults with haematological malignancies. J Antimicrob Agents Chemother 1999;44:569–72
   Web of Science ®Google Scholar
• Mehta J, Kelsey S, Chu P, et al. Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies. Bone Marrow Transplant 1997;20:39–43
   PubMed Web of Science ®Google Scholar
• Myint H, Bolam S, Orchard J, et al. Amphotericin B lipid complex (ABLC) is effective in neutropenic patients with radiological evidence of pulmonary fungal infections. Presented at the 23rd Annual Meeting of the European Group for Blood and Bone Marrow Transplantation and the 13th Meeting of the Nurses Group; Aix-les-Bains, France; 26 March, 1997 [Abstract]
   Google Scholar
• Myint H, Kyi AA, Winn RM. An open, non-comparative evaluation of the efficacy and safety of amphotericin B lipid complex as treatment of neutropenic patients with presumed or confirmed pulmonary fungal infections. J Antimicrob Agents Chemother 1998;41:417–26
   Google Scholar
• Sallah S, Semelka RC, Sallah W, Vainright JR, Philips DL. Amphotericin B lipid complex for the treatment of patients with acute leukemia and hepatosplenic candidiasis. Leuk Res 1999;23:995–9
   Google Scholar
• Mehta J, Powles R, Sirohi B, et al. Low-dose amphotericin B lipid complex (ABLC) is safe and effective as empiric antifungal therapy in immunocompromised patients with hematologic malignancies. Blood 2000;96:24
   PubMedGoogle Scholar
• Ostronoff M, Souto Maior AP, Sucupira A, et al. Prophylactic use of amphotericin B lipid complex (ABLC –Abelcet®) in patients (pts) undergoing hematologic intensive treatment and bone marrow transplantation. Abstract from 44th American Society of Hematology, 6–10 December 2002 (www.abstracts-online.com/abstracts/hemphiladelphia02/search/results.asp?Num = 0%2E9818644)
   Google Scholar
• Marty P, Rosenthal E. Treatment of visceral leishmaniasis: a review of current treatment practices. Expert Opin Pharmacother 2002;3(8):1101–8
   PubMedGoogle Scholar
• Sundar S, Murray HW. Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex. J Infect Dis 1996;173:762–5
   PubMed Web of Science ®Google Scholar
• Schaison G. Amphotericin B lipid complex (ABLC): treatment in children with invasive fungal infections. Presented at Simposium Internacional sobre Infecciones Fúngicas en el Recién Nacido; Rome, Italy, 6 June 1997 [Abstract]
   Google Scholar
• Walsh TJ, Whitcomb P, Piscitelli S, et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother 1997;41:1944–8
   PubMed Web of Science ®Google Scholar
• Kelly C, Cornish J, Marks D, Pamphillon D, Steward C, Oakhill A. The use of amphotericin B lipid complex in unrelated donor bone marrow transplantation. Bone Marrow Transplant 1998;21\(Suppl. 1):497
   Google Scholar
• Khairy Zaki A, Hamdy El sissy A. Amphotericin B lipid complex experience at the paediatric unit, National Cancer Institute, Cairo University. First International Congress of the Egyptian Group of Pediatric Oncology, 1999 [Abstract]
   Google Scholar
• Walsh TJ, Seibel NL, Arndt C, et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J 1999;18:702–8
   PubMed Web of Science ®Google Scholar
• Wiley JM, Walsh TJ, Matera JA. The use of amphotericin B lipid complex in pediatric cancer patients with invasive fungal infections. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 2000;40 [Abstract 390]
   Google Scholar
• Herbrecht R, Auvrignon A, Andrés E,et al. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients. Eur J Clin Microbiol Infect Dis 2001;20:77–82
   Google Scholar
• Adler-Shohet F, Waskin H, Lieberman JM. Amphotericin B lipid complex for neonatal invasive candidiasis. Arch Dis Child Fetal Neonatal Ed 2001;84:F131–3
   Google Scholar
• Adler-Shohet FC, Arrieta AC, Ross LA, et al. Amphotericin B lipid complex in neonates with invasive candidiasis. Clin Infect Dis 2001;33:1198
   Google Scholar
• Chisholm JC, Devine T, Mycroft J, Pinkerton CR. Tolerability of amphotericin B lipid complex (Abelcet) in children with malignant disease. Bone Marrow Transplant 1998;21\(Suppl. 1):S145, [Abstract 502]
   Google Scholar
• Allsup D, Chu P. A single centre analysis of the risk of nephrotoxicity and the efficacy of amphotericin B lipid complex for the treatment of suspected or proven fungal infections in patients receiving treatment for haematological malignancies. Presented at Trends in Invasive Infections 4; Barcelona, Spain; 5–8 November 1997
   Google Scholar
• Herzig R. Experience with amphotericin B lipid complex injection in the treatment of infectious complications after peripheral stem cell transplantation. Blood 1997;90\(Suppl. 1, pt 2 of 2):369b
   Google Scholar
• Seymour JF, Szer J, Grigg AP, Bardy P. Efficacy and toxicity of amphotericin B lipid complex (ABLC – Abelcet™) in patients with hematologic malignancies and invasive fungal infections failing standard therapy. Blood 1997;90\(Suppl. 1, pt 2 of 2):56b
   Google Scholar
• Stevens RC, McCormick JN, Rodman JH. Tolerance of amphotericin B lipid complex in pediatric cancer patients. Pharmacology 1997;17:1097
   Google Scholar
• Luke RG, Boyle JA. Renal effects of amphotericin B lipid complex. Am J Kidney Dis 1998;31:780–5
   PubMed Web of Science ®Google Scholar
• Aguado JM, González D, on behalf of the ABLC Pharmacosurveillance Study Group. Low nephrotoxicity in patients receiving amphotericin B lipid complex (ABLC). A pharmacosurveillance study in Spain. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 2000;40 [Abstract 390]
   Google Scholar
• Stalder T, Waskin H, Anderson A, Spurzem J, Dominguez E. High-dose amphotericin B lipid complex (ABLC) for treatment of invasive aspergillosis and zygomycosis. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 1998;38 [Abstract 489]
   Google Scholar
• Ringdén O, Jønsson V, Hansen M, Tollemar J, Jacobsen N. Severe and common side-effects of amphotericin B lipid complex (Abelcet). Bone Marrow Transplant 1998;22:733–4
   PubMed Web of Science ®Google Scholar
• Cook G, Franklin IM. Adverse drug reactions associated with the administration of amphotericin B lipid complex (Abelcet). Bone Marrow Transplant 1999;23:1325–6
   PubMed Web of Science ®Google Scholar
• Singhal S, Hastings JGM, Mutimer DJ. Safety of high-dose amphotericin B lipid complex. Bone Marrow Transplant 1999;24:116–7
   Google Scholar
• Furebring M, Öberg G, Sjölin J. Side-effects of amphotericin B lipid complex (Abelcet) in the Scandinavian population. Bone Marrow Transplant 2000;25:341–3
   PubMed Web of Science ®Google Scholar
• Gibson G, Edden M, Kasbekar N, Morgan A, Fishman N. Evaluation of adverse events associated with two lipid amphotericin products in patients who experience or are at risk to amphotericin B adverse events. Presented at the Focus on Fungal Infections 8; Orlando, Florida; 4–6 March, 1998 [Abstract 021]
   Google Scholar
• Wingard JR. Lipid formulations of amphotericins: are you a lumper or a splitter? Clin Infect Dis 2002;35:891–5
   PubMed Web of Science ®Google Scholar
• Matot I, Pizov R. Pulmonary extraction and accumulation of lipid formulations of amphotericin B. Crit Care Med 2000;28(7):2528–32 87.
   Google Scholar
• Slain D, Miller K, Khakoo R, Fisher M, Wierman T, Jozefczyk K. Infrequent occurrence of amphotericin B lipid complex-associated nephrotoxicity in various clinical settings at a university hospital: a retrospective study. Clin Ther 2002;24:1636–42
   PubMed Web of Science ®Google Scholar
• Salazar R, Peters J, Levine S, et al. Evaluation of renal toxicity of amphotericin B lipid complex (ABLC) in solid organ transplant (SOT) patients. Am J Respir Crit Care Med 1999; 159(Suppl.):A537
   Google Scholar
• Leather HL, Matera J, Waskins H, Wingard JR. Rates of nephrotoxicity in patients receiving amphotericin B lipid complex (ABLC): comparison between allogeneic BMT recipients with all patients given ABLC. Blood 1999;94\(Suppl. 1 pt 2):369b
   Google Scholar
• Singhal S, Hastings JGM, Mutimer DJ. Safety of high-dose amphotericin B lipid complex (Abelcet) in patients with liver disease. J Hepatol 1999;30\(Suppl. 1):174
   Google Scholar
• Strickland J, Yee G, Lister J, Lee L, Wingard J, Lee H. Nephrotoxicity of amphotericin B lipid complex in bone marrow transplant patients receiving cyclosporine. Pharmacother 1999;19:504 [Abstract 169]
   Google Scholar
• Barron RL, Kazakoff PW, Gabel I, Madinger NE. Novel hepatotoxicity of amphotericin B lipid complex in combination with cyclosporine a. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 1997;37 [Abstract 375]
   Google Scholar
• Barcia JP. Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B. Pharmacotherapy 1998;18:874–6
   PubMed Web of Science ®Google Scholar
• Rowles DM, Fraser SL. Amphotericin B lipid complex (ABLC)-associated hypertension: case report and review. Clin Infect Dis 1999;29:1564–5
   PubMed Web of Science ®Google Scholar
• Collazos J, Martínez E, Mayo J, Ibarra S. Pulmonary reactions during treatment with amphotericin B: review of published cases and guidelines for management. Clin Infect Dis 2001;33:e75–82
   Google Scholar
• Palmer SM, Drew RH, Whitehouse JD, et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplant 2001;72:545–8
   PubMed Web of Science ®Google Scholar
• Drew RH, Palmer SM, Davis R, Perfect JR. Invasive fungal infections (IFIs) in lung transplant recipients (LTR) receiving prophylactic aerosolized amphotericin B (aAmB) formulations. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 2002;42 [Abstract M–12360]
   Google Scholar
• Monforte V, Roman A, Gavalda J, et al. Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients. Transplantation 2003;75(9):1571–4
   PubMed Web of Science ®Google Scholar
• Anderson N, Drew R, Hayward S, Perfect J, Dukes Hamilton C. A successful program to optimize use of amphotericin B lipid complex (ABLC) at an academic medical center. Presented at the 35th Annual Meeting of the Infectious Diseases Society of America; San Francisco, California; 13–16 September 1997 [Abstract 151]
   Google Scholar
• Lapointe AK, Calandra T, Bille J, Glauser MP, Marchetti O. A 10-year review of the use of amphotericin B (AmB) in adult neutropenic cancer patients (Pt) in an university hospital. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 2000;40 [Abstract 390]
   Google Scholar
• Chan S, Forrest GN, Kleinberg M, Donnenberg MS, Standiford HC. Significant cost savings with implementation of lipid amphotericin B (L.A.B.). Guidelines in a university cancer center. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 2002;42 [Abstract O-999 and poster]
   Google Scholar
• Goff DA, Sierawski SJ. A clinical and economic analysis of amphotericin B lipid complex (ABLC) versus amphotericin B. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 1998;38 [Abstract 606]
   Google Scholar
• Greenberg RN, Cagnoni PJ, Prendergast MM, Tong KB. Pharmacoeconomics of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of persistently febrile neutropenic patients. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 2000;40 [Abstract 506]
   Google Scholar
• Baddour L with the CLEAR Steering Committee. Dosing experience with amphotericin B lipid complex (ABLC). Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 1999;39 [Abstract 573]
   Google Scholar
• Powles R, Sirohi B, Mehta J, et al. Low-dose amphotericin B lipid complex (ABLC) is safe and effective as empiric anti-fungal therapy in immunocompromised patients with hematologic malignancies. Presented at the 27th Annual Meeting European Group for Blood and Marrow Transplantation and 17th Nurses Group Meeting; Maastricht, The Netherlands; 25–28 March 2001 [Abstract]
   Google Scholar
• Subirà M, Martino R, Sureda A, et al. Safety and efficacy of low-dose amphotericin B lipid complex for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies. Methods Find Exp Clin Pharmacol 2001;23:505–10
   Google Scholar
• Rogers J, Conway A. Tolerability of low dose amphotericin B lipid complex (Abelcet®) for the treatment of pyrexia of unknown origin (PUO) in neutropenic cancer patients. Bone Marrow Transplant 1998;21\(Suppl. 1):493
   Google Scholar
• Cook G, Lever M, Tansey P, et al. Low dose amphotericin B lipid complex (Abelcet) is effective in the treatment of neutropenic pyrexia of unknown origin. Presented at the Fourth Congress of the European Haematology Association; Barcelona, Spain, 9–12 June 1999 (P0–0955)
   Google Scholar
• Myint H, Bolam S, Kyi AA, Creasy T. Prevention of recurrence of fungal pneumonia with prophylactic low dose amphotericin B lipid complex (Abelcet) following myelosuppressive chemotherapy. Presented at the 23rd Annual Meeting of the European Group for Blood and Bone Marrow Transplantation and the 13th Meeting of the Nurses Group; Aix-les-Bains, France; 26 March 1997 [Abstract]
   Google Scholar
• Myint H, Hall R, Bolam S, Kyi AA, Winn R. Pre-emptive therapy with low dose amphotericin B lipid complex (ABELCET) prevents recurrence of fungal pneumonia in immuno-compromised patients. Blood 1998;92\(Suppl. 1):4447
   Google Scholar
• Hall R, Bolam S, Kyi AA, Myint H. Prevention of recurrent fungal pneumonia with low dose amphotericin B lipid complex (Abelcet) in immunocompromised patients. Br J Haematol 1998;101\(Suppl. 1):60
   Google Scholar
• Singhal S, Ellis RW, Jones SG, et al. Targeted prophylaxis with amphotericin B lipid complex in liver transplantation. Liver Transplantation 2000;6:588–95
   PubMed Web of Science ®Google Scholar
• Chandrasekar PH, Cutright JL, Manavathu EK. In vitro activity of amphotericin B lipid complex in 2-drug combination with caspofungin against Aspergillus fumigatus. Presented at the 12th Focus on Fungal Infection Meeting, 20–22 March 2002 (http://www.doctorfungus.org/educatio/conf_highlights/focus12 /pdf/focus_9.pdf)
   Google Scholar
• Clevenbergh P, Jacobs F, Kentos A, Byl B, Collignon L, Moerman M, Serruys E, Thys JP. Compassionate use of amphotericin B lipid complex (Abelcet) in life-threatening fungal infections: report of 30 courses. Clin Microbiol Infect 1998;4(4):192–8
   PubMedGoogle Scholar
• Subirà M, Martino R, Gómez L, Martí JM, Estany C, Sierra J. Low-dose amphotericin B lipid complex versus conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematological malignancies. A randomized, controlled trial. Eur J Haematol 2004 (in press)
   Google Scholar